Topamax® Reduces Number Of Monthly Migraine Days In Chronic Migraine Patients

Sun, 30 Apr 2006 11:00 AM EST

... A study presented today at the annual meeting of the 8th European Headache Federation (EHF) demonstrated that chronic migraine sufferers treated preventively with TOPAMAX® (topiramate) experienced fewer migraine-related days per month than those treated with placebo. The TOP-CHROME (TOPiramate in CHROnic MigrainE) study was a 16-week, multicenter double-blind, randomised, placebo-controlled study involving 59 patients aged 18 to 65 who experienced chronic migraines, which are defined as a total of 15 or more migraine days every 4 weeks... click link for more info. ...